ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

NGM NGM Biopharmaceuticals Inc

1.54
0.00 (0.00%)
After Hours
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
NGM Biopharmaceuticals Inc NASDAQ:NGM NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 1.54 1.54 1.35 0 01:00:00

NGM Bio to Present at Two Upcoming Investor Conferences

29/05/2020 9:05pm

GlobeNewswire Inc.


NGM Biopharmaceuticals (NASDAQ:NGM)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more NGM Biopharmaceuticals Charts.

NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company focused on developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will present an overview of the company and provide a business update at two upcoming investor conferences.

Wednesday, June 3, 2020 Event:  Jefferies Virtual Healthcare Conference Time:  3:30 pm ET

Wednesday, June 10, 2020 Event: Goldman Sachs 41st Annual Global Healthcare Conference Time:  1:20 pm ET

A live webcast of these presentations will be available under the Investors and Media section of NGM’s website at https://ir.ngmbio.com/events-presentations. A replay of the presentation will be archived on NGM’s site for 30 days following the event.

About NGM Biopharmaceuticals, Inc. NGM is a biopharmaceutical company focused on developing novel therapeutics based on scientific understanding of key biological pathways underlying cardio-metabolic, liver, oncologic and ophthalmic diseases. We leverage our biology-centric drug discovery approach to uncover novel mechanisms of action and generate proprietary insights that enable us to move rapidly into proof-of-concept studies and deliver potential first-in-class medicines to patients. At NGM, we aspire to operate one of the most productive research and development engines in the biopharmaceutical industry, with multiple programs in clinical development. Visit us at www.ngmbio.com for more information.

Investor Contacts: Sylvia Wheeler and Alexandra Santosswheeler@wheelhouselsa.comasantos@wheelhouselsa.comir@ngmbio.comMedia Contact: Liz Melonemedia@ngmbio.com

1 Year NGM Biopharmaceuticals Chart

1 Year NGM Biopharmaceuticals Chart

1 Month NGM Biopharmaceuticals Chart

1 Month NGM Biopharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock